DOCSLIB.ORG

Sodium Stibogluconate: Therapeutic Use in the Management of Leishmaniasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sodium Stibogluconate: Therapeutic Use in the Management of Leishmaniasis Indian Journal of Biochemistry & Biophysics Vol. 45, February 2008, pp. 16-22 Minireview Sodium Stibogluconate: Therapeutic use in the Management of Leishmaniasis Jayeeta Roychoudhury and Nahid Ali* Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology 4 Raja S. C. Mullick Road, Kolkata-700032, India Received 30 July 2007; revised 17 December 2007 Leishmaniasis causes significant morbidity and mortality worldwide. The disease is endemic in developing countries of tropical regions, and in recent years economic globalization and increased travel has also spread to people in developed countries. In the absence of effective vaccines and vector-control measures, the main line of defense against the disease is chemotherapy. Organic pentavalent antimonials, including sodium stibogluconate have been the first-line drug for the treatment of leishmaniasis for the last several decades, and clinical resistance to these drugs has emerged as a primary obstacle to successful treatment and control. The present review describes the structure, activity, mode of action of sodium stibogluconate and mechanism of resistance towards this drug in leishmaniasis. Keywords: Sodium stibogluconate, Visceral leishmaniasis, Resistance, Pentavalent antimonials Introduction Leishmaniasis is endemic in 88 countries with an Leishmaniasis is a parasitic infection caused by the estimated 12–15 million individuals infected and an obligate, intracellular protozoan of the genus annual incidence of around 2 million3. The incidence of Leishmania (family : Trypanosomatidae). Over 15 fatal visceral leishmaniasis (VL) is rising, largely due to species of Leishmania capable of infecting humans urbanization and the human immunodeficiency virus have been classified into two main groups — Old (HIV) pandemic. Although most human cases occur as a World: L. major, L. tropica, L. aethiopica and the result of transmission by sandfly bites, contaminated L. donovani complex (L. donovani, L. infantum, blood products and sharing of needles by intravenous L. chagasi, L. archibaldi) and New World: drug users are other reported mechanisms of L. mexicana, L. amazonensis and Viannia complex transmission4. (e.g. L. brasiliensis, L. guyanensis)1. Leishmania has a Three major clinico-pathological categories have digenetic life cycle with an extracellular been recognized as cutaneous, muco-cutaneous and developmental stage in the insect vector, a female visceral form, each caused by distinct species. phlebotomine sandfly, and an intracellular Following treatment of VL, a different clinical developmental stage in mammals. In sandflies, the manifestation of infection with a condition termed parasites develop within the alimentary canal into ‘post-kala-azar dermal leishmaniasis’ might occur. flagellated and elongated form termed ‘promastigote’ The typical lesion of cutaneous leishmaniasis is a that eventually matures in the insect midgut into an chronic ulcer with histological features of an intense infective metacyclic promastigote. Inoculation into lymphoid and monocytic infiltrate with granuloma the mammalian host occurs when sandflies feed on formation. VL is characterized by dissemination of blood meal. A typical inoculum contains around parasites throughout the patient’s reticuloendothelial 100–1000 metacyclic promastigotes which quickly system and after an incubation period ranging from 1 become engulfed by the leucocytes, particularly month to 2 years, patients typically develop pyrexia, macrophages, neutrophils and dendritic cells. The wasting and hepatosplenomegaly5. parasites undergo a further transformation within 2 First line drugs against visceral leishmaniasis these cells to form amastigotes . The pentavalent antimonial derivatives meglumine ___________ antimoniate and sodium stibogluconate (SSG) (Fig. 1) *Corresponding author have been the main first line drugs for the treatment Tel: 91-33-2473-3491/6793/0492 Fax: 91-33-2473-0284/5197 of all forms of leishmaniasis including VL since 1940. E mail: [email protected] Meglumine antimoniate is marketed as Glucantime ROYCHOUDHURY & ALI: THERAPY OF LEISHMANIASIS WITH SSG 17 Ethiopian patients coinfected with HIV demonstrated SSG to be more effective than miltefosine, an orally administered drug11. During late 1970s and early 1980’s, different workers used different dose regimens of SSG to encounter the problem of unresponsiveness. Based on the pharmacokinetic study in Kenya, a prolonged dosage schedule of 10 mg/kg/day parenterally up to 60 days was recommended12. It was also observed that children’s tolerance for higher and prolonged dosage of SSG Fig. 1—Structure of antileishmanial pentavalent antimonial drugs: was better than adults. In 1982, WHO recommended (a) Pentostam or sodium stibogluconate and (b) glucantime or SSG in the dose of 20 mg/kg/day (maximum 850 mg) meglumine antimoniate for 20-30 days in fresh cases and for double duration (40-60 days) in relapse cases (Report of the informal and Prostibanate. SSG is available commercially as meeting on the chemotherapy of VL. WHO/TDR/ Pentostam, Solustibosan, Stibanate, and generic Chem/Leish/VL/1982-83/Narobi); Subsequently, sodium antimony gluconate. Amphotericin B (normal WHO (1990) recommended SSG in the dose of 20 or liposomized) is used as an alternative, but has 13,14 mg/kg/day for 28 days . An interesting aspect of significant disadvantage of severe toxicity and high therapy with SSG is an apparent resistance to cost for a disease prevalent in third-world countries. reinfection in previously treated mice. Resistance The demonstration of the efficacy of miltefosine is a was observed in liver, but not in spleen or bone breakthrough, but single point mutations can lead to marrow and lasted for at least 6 days after the resistance, which suggests that resistance to this drug 15 6 cessation of antimony treatment . may occur rapidly . In this scenario, a review on the structure, activity and mechanism of resistance of Species variation SSG could help for efficient monitoring of Variation in the clinical response to SSG and pentavalent antimonial resistance at sites, where it is meglumine antimoniate in VL has been a persistent endemic. problem in the treatment of leishmaniasis over the past 60 years. One explanation for this phenomenon Chemical structure and properties of sodium is the intrinsic difference in species sensitivity to stibogluconate these drugs. In general, studies using the SSG is chemically synthesized mixture formed amastigote-macrophage model, L. donovani and by chemical reaction of stibonic and gluconic acids, L. brasiliensis have been found to be 3- to 5-fold rather than a single compound. Fractional analysis more sensitive to SSG than L. major, L. tropica, of SSG used against L. panamensis amastigotes and L. mexicana16,17. demonstrated that the activity is associated with multiple chemical species. Pentostam is composed Toxicity of sodium stibogluconate of multiple species having molecular weights Although pentavalent antimonial compounds are ranging from 100-4000 Da and a low osmolarity of the most widely used drugs for the treatment of 789 milliOsmole for a 100 mg antimony/ml leishmaniasis, the side effects are frequent18. Side solution. In the dog, SSG is rapidly excreted from effects include abdominal pain, vomiting, nausea, the body7. Similar results have been reported for fatigue, headache, increase of liver enzymes, human patients given antimonial drugs8. The main nephrotoxicity, arthralgia, fever, rash, cough, route of excretion for antimonial drugs is via the pneumonia, pancytopenia and reversible peripheral kidney9. neuropathy. Recent studies suggest that elevation of amylase and lipase is common and that a subset of Treatment against leishmaniasis patients suffers clinically significant pancreatitis19-21. In areas with >94% response rates to antimonials, Serious side effects, such as atrial arrhythmia and generic SSG remains the most effective option for VL fibrillation, and ventricular arrhythmia, tachycardia treatment, mainly due to low cost10. A comparative and fibrillation are rare20-22. It should be kept in mind study between SSG and miltefosine treatment among that pentavalent antimony is contra-indicated in 18 INDIAN J. BIOCHEM. BIOPHYS., VOL. 45, FEBRUARY 2008 patients with myocarditis, hepatitis and pancreatitis. Mechanisms of action and resistance Even the normal dose of SSG can lead to both It is now generally accepted that all pentavalent cardiotoxicity and hematotoxicity, because of its antimonials [Sb (V)] are pro-drugs that require cumulative effect. Therefore, the patients with biological reduction to the trivalent form [Sb (III)] for leishmaniasis being treated with antimony compounds antileishmanial activity. However, site (amastigotes or should be observed cautiously for signs of cardiologic macrophage) and mechanism of reduction (enzymatic and hematologic changes23,24. Neurological or non-enzymatic) remain controversial. Studies manifestations of SSG have been documented in indicate that axenic amastigotes are susceptible to Sb Sudan, where exercise of Pentostam led to cases of (V) but not the promastigotes, suggesting that some cerebellar ataxia25. stage-specific reduction occurs in this life cycle stage36. But the mechanism by which amastigotes Clinical resistance reduce Sb (V) is not clear. Both glutathione and Although the selection of pentavalent antimonial trypanothione can non-enzymatically reduce Sb (V) to resistant Leishmania has long been a part of Sb (III), particularly under acidic
Load more

Recommended publications
  • Review Article Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions
    SAGE-Hindawi Access to Research Molecular Biology International Volume 2011, Article ID 571242, 23 pages doi:10.4061/2011/571242 Review Article Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions Arun Kumar Haldar,1 Pradip Sen,2 and Syamal Roy1 1 Division of Infectious Diseases and Immunology, Indian Institute of Chemical Biology, Council of Scientific and Industrial Research, 4 Raja S. C. Mullick Road, Kolkata West Bengal 700032, India 2 Division of Cell Biology and Immunology, Institute of Microbial Technology, Council of Scientific and Industrial Research, Chandigarh 160036, India Correspondence should be addressed to Syamal Roy, [email protected] Received 18 January 2011; Accepted 5 March 2011 Academic Editor: Hemanta K. Majumder Copyright © 2011 Arun Kumar Haldar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In the recent past the standard treatment of kala-azar involved the use of pentavalent antimonials Sb(V). Because of progressive rise in treatment failure to Sb(V) was limited its use in the treatment program in the Indian subcontinent. Until now the mechanism of action of Sb(V) is not very clear. Recent studies indicated that both parasite and hosts contribute to the antimony efflux mechanism. Interestingly, antimonials show strong immunostimulatory abilities as evident from the upregulation of transplantation antigens and enhanced T cell stimulating ability of normal antigen presenting cells when treated with Sb(V) in vitro. Recently, it has been shown that some of the peroxovanadium compounds have Sb(V)-resistance modifying ability in experimental infection with Sb(V) resistant Leishmania donovani isolates in murine model.
    [Show full text]
  • T. Cruzi Invasion Summary Leishmania Phagosome
    What is happening in invasion? T. cruzi invasion- non phagocytic Phagocytosis Active invasion Yeast Trypanosoma cruzi Actin filaments Lamp-1 T. cruzi invasion summary Leishmania phagosome Treatment for kinetoplastid diseases HAT Early (these drugs cannot cross the blood/brain barrier) Suramin (1916) highly charged compound Mode of action (?) - inhibits metabolic enzymes (NAD+) Pentamidine (some resistance) Mode of action (?) - likely multiple targets Differential uptake of drug - parasite conc. mM quantites Late Melarsoprol (lipophilic) (1947) Highly toxic arsenical - up to 10% treated die Mode of action (?) - possibly energy metabolism Eflornithine (drug has similar affinity to mammalian enzyme) suicide inhibitor of ornithine decarboxylase blocking polyamine biosynthesis Treatments for HAT 1985 2005 Early Stage First-line drugs Pentamidine Pentamidine Suramin Suramin Clinical trials - DB 289 (Phase III) Pre-clinical stage - - Late-stage/CNS First-line drugs Melarsoprol Melarsoprol Eflornithine Clinical trials - Nifurtimox + Eflornithine Pre-clinical stage - - Treatment for kinetoplastid diseases Chagas Acute Nifurtimox 60-90 days Mode of action (?) ROS - then DNA damage Benznidazole 30-120 days Mode of action - thought to inhibit nucleic acid synthesis (ROS?) Chronic Virtually untreatable - just treat symptoms Treatments for Chagas 1985 2005 Acute Stage First-line drugs Benznidazole Benznidazole Nifurtimox Nifurtimox Clinical trials Allopurinal Indeterminate Stage Clinical trials - Benznidazole Chronic Stage First-line drugs -
    [Show full text]
  • Drugs for Amebiais, Giardiasis, Trichomoniasis & Leishmaniasis
    Antiprotozoal drugs Drugs for amebiasis, giardiasis, trichomoniasis & leishmaniasis Edited by: H. Mirkhani, Pharm D, Ph D Dept. Pharmacology Shiraz University of Medical Sciences Contents Amebiasis, giardiasis and trichomoniasis ........................................................................................................... 2 Metronidazole ..................................................................................................................................................... 2 Iodoquinol ........................................................................................................................................................... 2 Paromomycin ...................................................................................................................................................... 3 Mechanism of Action ...................................................................................................................................... 3 Antimicrobial effects; therapeutics uses ......................................................................................................... 3 Leishmaniasis ...................................................................................................................................................... 4 Antimonial agents ............................................................................................................................................... 5 Mechanism of action and drug resistance ......................................................................................................
    [Show full text]
  • Topical Treatment of Cutaneous Leishmaniasis
    Topical Treatment of Cutaneous Leishmaniasis Joseph EI-On, Ph.D., Rita Livshin, M.D., Zvi Even-Paz, M.D. , David Hamburger, Ph.D., and Louis Weinrauch, M. D . Department of Microbio logy and Immunology, Facult y of Hea lth Sciences, Dcn G urion University of the N cgev UE-O), Deer­ Sheva; Departmcnt of Dcrmatology, Hadassah Universi ty H ospital, Hebrcw University Had assa h Mcdical School (R L, ZE-P, LW), j erusalem; Teva Pharm aceutica l In dustries Ltd. (01-1 ), j erusa lem, Israel Six ty- seven patients, 19 fem :ll es and 48 m ales, 4-66 years develo pments did not affect the clinical he:ding process o ld , sufferin g fro m lesions o f cutaneous leishmaniasis which was generall y completed in a period of 10-30 d ays were treated to pica ll y with an o intme nt comprising 15% after termination of trea tment. In addition, 94% of the paro m o mycin sulfate and 12% m eth ylbenzethonium chl o­ treated lesio n s healed with little o r no scarring. N o adverse ride in white soft pa raffin (P-ointment, U .K . patent clinica l or laboratory side effe cts w ere observed except fo r GBll7237A). After 10 d ays of treatment, twice daily, the a burning sensation at the site of trea tment. Parasites iso_ lesio ns in 72% of the treated pati ents were free of parasites, lated fro m patients w ho failed to respond to topical treat_ 15% becam e free with in an additional 20 d ays, witho ut m ent were found to be susceptible to PR-MBC I in both further trea tment, and 13% failed to respond.
    [Show full text]
  • 204684Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204684Orig1s000 SUMMARY REVIEW Division Director Review NDA 204684, Impavido (miltefosine)Capsules 1. Introduction NDA 204684 is submitted by Paladin Therapeutics, Inc., for the use of miltefosine for the treatment of visceral, cutaneous, and mucosal leishmaniasis in patients ≥12 years of age. The proposed dosing regimen is one 50 mg capsule twice daily with food for patients weighing 30- 44 kg (66-97 lbs.) and one 50 mg capsule three times daily with food for patients weighing ≥ 45 kg (≥ 99 lbs.). Leishmaniasis is caused by obligate intracellular protozoa of the genus Leishmania. The clinical manifestations are divided into three syndromes of visceral leishmaniasis, cutaneous leishmaniasis, and mucosal leishmaniasis. A single species of Leishmania can produce more than one clinical syndrome and each of the syndromes can be caused by more than species of Leishmania. Human infection is caused by about 21 of 30 species that infect mammals. These include the L. donovani complex with 2 species (L. donovani, L. infantum [also known as L. chagasi in the New World]); the L. mexicana complex with 3 main species (L. mexicana, L. amazonensis, and L. venezuelensis); L. tropica; L. major; L. aethiopica; and the subgenus Viannia with 4 main species (L. (V.) braziliensis, L. (V.) guyanensis, L. (V.) panamensis, and L. (V.) peruviana). Leishmaniasis is transmitted by the bite of infected female phlebotomine sandflies. The promastigotes injected by the sandflies during blood meals are phagocytized by macrophages and other types of mononuclear phagocytic cells and transform into amastigotes. The amastigotes multiply by simple binary fission and lead to rupture of the infected cell and invasion of other reticuloendothelial cells.1 Miltefosine is an alkyl phospholipid analog with in vitro activity against the promastigote and amastigote stages of Leishmania species.
    [Show full text]
  • Guidelines for Diagnosis, Treatment and Prevention of Visceral Leishmaniasis in South Sudan
    Guidelines for diagnosis, treatment and prevention of visceral leishmaniasis in South Sudan Acromyns DAT Direct agglutination test FDA Freeze – dried antigen IM Intramuscular IV Intravenous KA Kala–azar ME Mercaptoethanol ORS Oral rehydration salt PKDL Post kala–azar dermal leishmaniasis RBC Red blood cells RDT Rapid diagnostic test RR Respiratory rate SSG Sodium stibogluconate TFC Therapeutic feeding centre TOC Test of cure VL Visceral leishmaniasis WBC White blood cells WHO World Health Organization Table of contents Acronyms ...................................................................................................................................... 2 Acknowledgements ....................................................................................................................... 4 Foreword ...................................................................................................................................... 5 1. Introduction ........................................................................................................................... 7 1.1 Background information ............................................................................................... 7 1.2 Lifecycle and transmission patterns ............................................................................. 7 1.3 Human infection and disease ....................................................................................... 8 2. Diagnosis ..............................................................................................................................
    [Show full text]
  • Identification and Characterization of Novel Anti-Leishmanial Compounds
    Identification and Characterization of Novel Anti-leishmanial Compounds Bilal Zulfiqar Master of Philosophy, Doctor of Pharmacy Discovery Biology Griffith Institute for Drug Discovery School of Natural Sciences Griffith University Submitted in fulfilment of the requirements of the degree of Doctor of Philosophy October 2017 ABSTRACT ABSTRACT Leishmaniasis is characterized as a parasitic disease caused by the trypanosomatid protozoan termed Leishmania. Leishmaniasis is endemic in 98 countries around the globe with increased cases of morbidity and mortality emerging each day. The mode of transmission of this disease is via the bite of a sand fly, genus Phlebotomus (Old World) and Lutzomyia (New World). The life cycle of Leishmania parasite exists between the sand fly (promastigote form) and the mammalian host (amastigote form). Leishmaniasis can be characterized as cutaneous, muco-cutaneous or visceral leishmaniasis based on clinical manifestations exhibited in infected individuals. Although leishmaniasis is treatable, it faces challenges largely due to emerging resistance and extensive toxicity for current drugs. Therapeutic efficacy varies depending upon the species, symptoms and geographical regions of the Leishmania parasite. The drug discovery pipeline for neglected trypanosomatid diseases remains sparse. In particular, the field of leishmaniasis drug discovery has had limited success in translating potential drug candidates into viable therapies. Currently there are few compounds that are clinical candidates for leishmaniasis, it is therefore essential that new compounds that are active against Leishmania are identified and evaluated for their potential to progress through the drug discovery pipeline. In order to identify new therapeutics, it is imperative that robust, biologically relevant assays be developed for the screening of anti-leishmanial compounds.
    [Show full text]
  • Manual for the Diagnosis and Treatment of Leishmaniasis
    Republic of the Sudan Federal Ministry of Health Communicable and Non-Communicable Diseases Control Directorate MANUAL FOR THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS November 2017 Acknowledgements The Communicable and Non-Communicable Diseases Control Directorate (CNCDCD), Federal Ministry of Health, Sudan, would like to acknowledge all the efforts spent on studying, controlling and reducing morbidity and mortality of leishmaniasis in Sudan, which culminated in the formulation of this manual in April 2004, updated in October 2014 and again in November 2017. We would like to express our thanks to all National institutions, organizations, research groups and individuals for their support, and the international organization with special thanks to WHO, MSF and UK- DFID (KalaCORE). I Preface Leishmaniasis is a major health problem in Sudan. Visceral, cutaneous and mucosal forms of leishmaniasis are endemic in various parts of the country, with serious outbreaks occurring periodically. Sudanese scientists have published many papers on the epidemiology, clinical manifestations, diagnosis and management of these complex diseases. This has resulted in a better understanding of the pathogenesis of the various forms of leishmaniasis and has led to more accurate and specific diagnostic methods and better therapy. Unfortunately, many practitioners are unaware of these developments and still rely on outdated diagnostic procedures and therapy. This document is intended to help those engaged in the diagnosis, treatment and nutrition of patients with various forms of leishmaniasis. The guidelines are based on publications and experience of Sudanese researchers and are therefore evidence based. The guidelines were agreed upon by top researchers and clinicians in workshops organized by the Leishmaniasis Control response at the Communicable and Non-Communicable Diseases Control Directorate, Federal Ministry of Health, Sudan.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Public Health Goal for ANTIMONY in Drinking Water
    Public Health Goal for ANTIMONY in Drinking Water Prepared by Pesticide and Environmental Toxicology Section Office of Environmental Health Hazard Assessment California Environmental Protection Agency December 1997 LIST OF CONTRIBUTORS PHG PROJECT MANAGEMENT REPORT PREPARATION SUPPORT Project Officer Author Administrative Support Anna Fan, Ph.D. Lubow Jowa, Ph.D. Edna Hernandez Coordinator Chemical Prioritization Primary Reviewer Laurie Bliss Report Outline Robert Brodberg, Ph.D. Sharon Davis Joseph Brown, Ph.D. Kathy Elliott Coordinator Secondary Reviewer Vickie Grayson David Morry, Ph.D. Michael DiBartolomeis, Ph.D. Michelle Johnson Yi Wang, Ph.D. Juliet Rafol Final Reviewers Genevieve Shafer Document Development Anna Fan, Ph.D. Tonya Turner Michael DiBartolomeis, Ph.D. William Vance, Ph.D. Coordinator Library Support George Alexeeff, Ph.D. Editor Mary Ann Mahoney Hanafi Russell, M.S. Michael DiBartolomeis, Ph.D. Valerie Walter Yi Wang, Ph.D. Website Posting Public Workshop Robert Brodberg, Ph.D. Michael DiBartolomeis, Ph.D. Edna Hernandez Coordinator Laurie Monserrat, M.S. Judy Polakoff, M.S. Judy Polakoff, M.S. Organizer Hanafi Russell, M.S. Methodology/Approaches/ Review Comments Joseph Brown, Ph.D. Robert Howd, Ph.D. Coordinators Lubow Jowa, Ph.D. David Morry, Ph.D. Rajpal Tomar, Ph.D. Yi Wang, Ph.D. We thank the U.S. EPA’s Office of Water, Office of Pollution Prevention and Toxic Substances, and National Center for Environmental Assessment for their peer review of the PHG documents, and the comments received from all interested parties. ANTIMONY in Drinking Water ii December 1997 California Public Health Goal (PHG) PREFACE Drinking Water Public Health Goal of the Office of Environmental Health Hazard Assessment This Public Health Goal (PHG) technical support document provides information on health effects from contaminants in drinking water.
    [Show full text]
  • Redalyc.Influence of Gentamicine on the Pharmacokinetic of A
    Archivos Venezolanos de Farmacología y Terapéutica ISSN: 0798-0264 [email protected] Sociedad Venezolana de Farmacología Clínica y Terapéutica Venezuela Vásquez de Ricciardi, Laura; Scorza, José Vicente; Vicuña-Fernández, Nelson; Petit de Peña, Yaneira; Bendezú, Herminia; Vasquez, Libia; Yanez, Carlos Influence of gentamicine on the pharmacokinetic of a pentavalent antimonial compound Glucantime® Influence of gentamicine on Glucantime kinetic Archivos Venezolanos de Farmacología y Terapéutica, vol. 25, núm. 2, 2006, pp. 60-63 Sociedad Venezolana de Farmacología Clínica y Terapéutica Caracas, Venezuela Disponible en: http://www.redalyc.org/articulo.oa?id=55925204 Cómo citar el artículo Número completo Sistema de Información Científica Más información del artículo Red de Revistas Científicas de América Latina, el Caribe, España y Portugal Página de la revista en redalyc.org Proyecto académico sin fines de lucro, desarrollado bajo la iniciativa de acceso abierto Influence of gentamicine on the pharmacokinetic of a pentavalent antimonial compound Glucantime® Influence of gentamicine on Glucantime kinetic Laura Vásquez de Ricciardi 1, José Vicente Scorza 2, Nelson Vicuña-Fernández 3, Yaneira Petit de Peña 4, Herminia Bendezú 5, Libia Vasquez 6, Carlos Yanez 7 1 Doctora en Ciencias Médicas. Laboratorio de Farmacología., Facultad de Medicina Escuela de Medicina Valera. ULA. 2 Doctor en Parasitología. Centro de Investigaciones Parasitológicas ¨José W. Torrealba¨ NURR. ULA. 3 Médico Especialista en Farmacocinética. Laboratorio de Farmacología y Toxicología Facultad de Medicina ULA. Mérida, Venzuela. 4 Doctora en Química. Laboratorio de Espectroscopía Molecular. Facultad de Ciencias. La Hechicera. ULA. 5 Magister en Protozoología. Centro de Investigaciones Parasitológicas ¨José W. Torrealba¨ NURR, ULA. 6 Medico Microbiologo. Laboratorio de Microbiología.
    [Show full text]
  • N-Metil Glucamine and Topical Miltefosine Association In
    Received: August 28, 2006 J. Venom. Anim. Toxins incl. Trop. Dis. Accepted: April 4, 2007 V.13, n.3, p.598-606, 2007. Abstract published online: April 5, 2007 Original paper. Full paper published online: August 31, 2007 ISSN 1678-9199. INEFFICACY OF THE ASSOCIATION N-METHYL GLUCAMINE AND TOPICAL MILTEFOSINE IN THE TREATMENT OF EXPERIMENTAL CUTANEOUS LEISHMANIASIS BY Leishmania (Leishmania) amazonensis SAMPAIO R. N. R. (1), LUCAS I. C. (1), TAKAMI H. L. (1) (1) Laboratory of Dermatomycology, University of Brasília, Brazil. ABSTRACT: Pentavalent antimonial (SbV) is the first treatment for cutaneous leishmaniasis (CL). Other drugs present similar side effects and higher cost. Oral miltefosine is effective to treat kala-azar. The aim of the present study was to compare the efficacy of glucamine (SbV) plus topical miltefosine with glucamine in the treatment of CL. Eighty isogenic C57BL/6 mice were inoculated with Leishmania (Leishmania) amazonensis and divided into two groups: one group was treated with SbV associated with miltefosine, and the other group received SbV plus saline solution. Groups were evaluated according to the diameter of the inoculated foot pad, the culture, and the parasite count using the limiting dilution assay. There was not statistical difference. The efficacy of glucamine in CL treatment did not increase when associated with topical miltefosine. KEY WORDS: Cutaneous Leishmaniasis, Miltefosine, N-methyl glucamine. CONFLICTS OF INTEREST: There is no conflict. CORRESPONDENCE TO: RAIMUNDA NONATA RIBEIRO SAMPAIO, Universidade de Brasília, Campus Universitário Darcy Ribeiro, Asa Norte, Brasília, 70910-900, DF, Brasil. Phone: +55 61 307 2502. Fax: +55 61 367 3825. Email: [email protected].
    [Show full text]